-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, WwaRZA9g/oYK9rS23XM8eoNj0jB/RDFpx/5A2VPy9RhyHcXG8Too4gDVrXXG60r/ HidI//4DWNrOwILo1R8cJw== 0001193125-03-077966.txt : 20031112 0001193125-03-077966.hdr.sgml : 20031111 20031112120530 ACCESSION NUMBER: 0001193125-03-077966 CONFORMED SUBMISSION TYPE: 15-12G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20031112 EFFECTIVENESS DATE: 20031112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ESSENTIAL THERAPEUTICS INC CENTRAL INDEX KEY: 0001010915 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943186021 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 15-12G SEC ACT: 1934 Act SEC FILE NUMBER: 000-28006 FILM NUMBER: 03992138 BUSINESS ADDRESS: STREET 1: 78 FOURTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: (781) 647-5554 MAIL ADDRESS: STREET 1: 78 FOURTH AVENUE CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: MICROCIDE PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960319 15-12G 1 d1512g.htm FORM 15 FORM 15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 15

 

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G)

OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS

UNDER SECTIONS 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number 0-28006

 

ESSENTIAL THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

78 Fourth Avenue

Waltham, MA 02451

(781) 647-5554

(Address, including zip code, and telephone number, including area code,

of registrant’s principal executive offices)

 

Rights to Purchase Shares of Series A Preferred Stock, par value $0.001 per share

Common Stock, par value $0.001 per share

(Title of each class of securities covered by this Form)

 

None

(Titles of all other classes of securities for which a duty to file reports under

Section 13(a) or 15(d) remains)

 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

 

    

Rule 12g-4(a)(1)(i)    

Rule 12g-4(a)(1)(ii)    

Rule 12g-4(a)(2)(i)    

Rule 12g-4(a)(2)(ii)    

  

x

¨

¨

¨

   

Rule 12h-3(b)(1)(i)

Rule 12h-3(b)(1)(ii)

Rule 12h-3(b)(2)(i)

Rule 12h-3(b)(2)(ii)

Rule 15d-6

   

x

¨

¨

¨

¨

     

 

Approximate number of holders of record as of the certification or notice date: none

 

Pursuant to the requirements of the Securities Exchange Act of 1934 Essential Therapeutics, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

 

Date: November 11, 2003               By:  

/s/    MARK SKALETSKY

           

Mark Skaletsky

Chief Executive Officer

 -----END PRIVACY-ENHANCED MESSAGE-----